A Registry for People With T-cell Lymphoma

Summary

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Conditions

• T-cell Lymphoma
• NK-Cell Lymphoma
• T-cell Prolymphocytic Leukemia
• T-cell Large Granular Lymphocytic Leukemia
• Chronic Lymphoproliferative Disorder of NK Cells
• Aggressive NK-cell Leukemia
• Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)
• Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood
• Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form
• Hydroa Vacciniforme-Like Lymphoproliferative Disorder
• Adult T-cell Leukemia/Lymphoma
• Extranodal NK/T-cell Lymphoma, Nasal Type
• Enteropathy-associated T-cell Lymphoma
• Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
• Intestinal T-Cell Lymphoma, Not Otherwise Specified
• Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
• Hepatosplenic T-cell Lymphoma
• Subcutaneous Panniculitis-Like T-Cell Lymphoma
• Mycosis Fungoides
• Sezary Syndrome
• Primary Cutaneous Anaplastic Large Cell Lymphoma
• Primary Cutaneous T-cell Lymphoma
• Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma
• Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma
• Peripheral T-Cell Lymphoma, Not Otherwise Specified
• Angioimmunoblastic T-cell Lymphoma
• Follicular T-Cell Lymphoma
• Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
• Anaplastic Large Cell Lymphoma, ALK-Positive
• Anaplastic Large Cell Lymphoma, ALK-negative
• Breast Implant-Associated Anaplastic Large Cell Lymphoma

Interventions

OTHER

Optional Blood Sample and Nail Sample

Participants may provide optional research blood and nail samples for biobanking and future use

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center

  lead OTHER

Principal Investigators

• Steven Horwitz, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-07-27

Primary Completion

2030-07-27

Completion

2030-07-27

Countries

• United States

Study Locations